Special Drug Use Investigation of Glucobay OD
NCT01685502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2289
Last updated 2014-10-20
Summary
The objective of this study is to assess the efficacy and safety under practical use of Glucobay OD. A total of 5,000 patients are to be enrolled to the study and assessed during 1 year observation period.
Conditions
Interventions
- DRUG
-
Glucobay ODT (Acarbose, BAYG5421)
Patients treated with Glucobay OD under practical manner
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2013-09-30
- Completion
- 2014-08-31
Countries
- Japan
More Related Trials
-
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01468181 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
NCT02227849 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01368081 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Tolerability of Acarbose in Healthy Individuals
NCT05542849 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
NCT02750410 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
NCT03645421 ·Status: COMPLETED ·Phase: PHASE2
-
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).
NCT00754130 ·Status: COMPLETED ·Phase: PHASE1
-
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
NCT01010100 ·Status: COMPLETED ·Phase: PHASE3
-
The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor
NCT02500186 ·Status: COMPLETED ·Phase: NA
-
Along-term Study of OPC-262 in Patients With Type 2 Diabetes
NCT01634282 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes
NCT02222350 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03315780 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
NCT02292433 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
NCT00859755 ·Status: COMPLETED ·Phase: PHASE1
-
A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients
NCT03805191 ·Status: UNKNOWN
-
Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy
NCT01261143 ·Status: COMPLETED ·Phase: PHASE3
-
Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects
NCT02162355 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
NCT02288273 ·Status: COMPLETED ·Phase: PHASE4
-
Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell
NCT03180281 ·Status: UNKNOWN ·Phase: NA
-
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
NCT02157298 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
NCT00755846 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
NCT01940965 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
NCT00530309 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
NCT01282970 ·Status: COMPLETED ·Phase: PHASE1
-
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
NCT00558571 ·Status: COMPLETED ·Phase: PHASE1